ÂÜÀòÂÒÂ×

Dr. Dirk Huebner is the Exacis CMO, almost 30 years of academic and industry based clinical drug development experience within the fields of oncology and immune-oncology. Over these years Dr. Huebner led multiple clinical programs in hematologic as well as solid tumor malignancies from phase 1 to phase 3 development stages. Prior to joining Exacis Dr. Huebner served as the CMO of Mersana with oversight of development of the ADC pipeline. Prior to joining Mersana, Dr. Huebner served as Vice President and Head of Development for Boston Biomedical where he built a robust clinical development team and oversaw the development of several early-stage compounds as well as of the napabucasin phase 3 program.

Prior to that, he spent six years at Millennium / Takeda Oncology as Executive Medical Director where he served as the global clinical lead for ADCETRIS® (brentuximab vedotin), an ADC that is indicated for the treatment of Hodgkin lymphoma and certain CD30 positive T-cell lymphomas. In that role, he led the regulatory approval of ADCETRIS in Europe and the design and implementation of the subsequent registration-enabling studies for the compound. Prior to Takeda, he held global roles of increasing responsibility in global clinical drug development at Genzyme, Roche, and Bristol-Myers Squibb. Dr. Huebner received his Medical Doctor degree from Freie Universitaet Berlin, Germany and pursued a medical residency at the Department of Urology, University Hospital Eppendorf, Hamburg.